Overview

The Repatriation Medical Authority Instrument No. 61 of 2011, enacted under the Veterans’ Entitlements Act 1986, addresses the issue of amending the criteria for recognising malignant neoplasm of the ovary as a condition related to service in the Australian Defence Force. This legislative instrument was developed by the Repatriation Medical Authority, which was tasked with investigating and updating the relevant Statement of Principles to better reflect current medical understanding and evidence. The primary policy objective behind this amendment is to ensure that the criteria for recognising service-related conditions are based on the most accurate and up-to-date scientific evidence, thereby providing appropriate recognition and benefits to affected veterans. The instrument replaces and renumbers certain factors related to ionising radiation and removes outdated definitions to streamline the recognition process and align it with contemporary medical research.

Scope and Application

The Repatriation Medical Authority Instrument No. 61 of 2011 amends the Statement of Principles concerning malignant neoplasm of the ovary under the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This legislative instrument applies to veterans and service personnel who have been diagnosed with malignant neoplasm of the ovary, focusing on the factors associated with the condition, specifically replacing and re-numbering certain factors and clauses to more accurately reflect the current understanding of the disease’s causes. The amendment aims to ensure that veterans and their dependants receive appropriate recognition and compensation for conditions linked to their service. Geographically, the application of this instrument is governed by the provisions of the VEA and MAC Act, which extend throughout the Commonwealth of Australia, ensuring that all eligible veterans and their families across the nation are covered. The instrument does not specify any exclusions or exemptions but follows the legislative framework that inherently includes eligibility criteria for veterans’ benefits. This legislative amendment is effective from the date specified in the instrument, as mandated by the Legislative Instruments Act 2003.

Key Provisions

The Repatriation Medical Authority Instrument No. 61 of 2011 amends the Statement of Principles Instrument No. 70 of 2009, which concerns malignant neoplasm of the ovary, under subsection 196B(2) and (8) of the Veterans’ Entitlements Act 1986 (VEA). This amendment introduces a new factor relating to 'ionising radiation' and replaces existing factors to ensure that the criteria for assessing this condition are updated and reflect current understanding (sections 2 and 3). The changes include replacing factor 6(i) with the new factor on ionising radiation, deleting factor 6(j) because it is now covered under the new factor, and re-numbering factor 6(k) to 6(j). Additionally, clause 7 is revised to align with these changes, and the definition of "cumulative equivalent dose" in clause 9 is updated, while the definition of "atomic radiation" is removed (section 2). The authority also specifies an effective date for these amendments in line with subsection 12(1)(a) of the Legislative Instruments Act 2003 (section 3). The Authority imposed obligations on itself and relevant stakeholders to ensure a thorough investigation and review process. This included advertising its intention to investigate in the Government Notices Gazettes on 1 September 2010 and 3 November 2010, and distributing notices to various organisations and individuals representing veterans, service personnel, and their dependants (section 4). The Authority sought submissions from the Repatriation Commission, organisations, persons specified in section 196E of the VEA, and any experts in the field. However, no submissions were received during the investigation (section 5). The final determination of this Instrument concludes the investigation, making the new criteria for assessing malignant neoplasm of the ovary effective and binding. Breaches of the provisions set out in this Instrument could have legal consequences, although specific offences and penalties are not detailed within the text provided. The Instrument itself references the need to adhere to the legislative requirements established under the VEA and the Legislative Instruments Act 2003. Failure to comply with these legislative requirements could potentially lead to legal challenges or other repercussions as defined by the relevant Acts. For detailed information on potential penalties, one would need to refer to the specific sections of the VEA and the Legislative Instruments Act 2003.